Paolo Tarantino: Intersecting data with the MAT2A inhibitor IDE397 in MTAPdel lung and urothelial cancer
Paolo Tarantino shared a post by Bio Stocks on X, adding: .
“Intersecting data with the MAT2A inhibitor IDE397 in MTAPdel lung and urothelial cancer.
The drug is designed to achieve synthetic lethality in tumors with MTAP deletions (15% of solid tumors, in the setting of 9p21 loss).”
Quoting the post by Bio Stocks:
“IDEAYA Biosciences Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer.”
Read the article on the following websites:
prnewswire.com
biospace.com
Source: Paolo Tarantino/X and Bio Stocks/X
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023